Abstract

Introduction: Benign prostatic hyperplasia, one of the most common diseases among ageing men. BPH prevalence increases from approximately 50% at 60 years to 90% in men older than 85 years. Lower urinary tract system significant impact on the overall quality of life.The treatment options include: 1. Watchful waiting: if the symptoms are mild and not causing any change. 2. Medical treatment - Alfa-receptor antagonists, 5 alfa-reductase antagonists, antimuscarinics, phosphodiesterase 5 inhibitors and their combinations. 3. Surgical management is preferred in patients with an IPSS score more than 19-traditional monopolar Transurethral resection of the prostate (TURP), Prostatic Urethral Lift. Aims and Objectives Aim of the study: To study the outcomes of medical management of BPH based on the IPSS. Objectives of the study: Primary Objective: To study the outcomes of medical management of BPH in terms of reduction of IPSS, change in prostate size, post-void residual volume as assessed by USG with medical management. Secondary Objectives: 1. To study the age distribution in BPH 2. To study the symptomatology of BPH. This prospective observational study was carried out. A total of 55 patients presenting with lower urinary tract symptoms secondary to BPH were enrolled for the study. International Prostate Symptom Score was assessed on presentation and patient was started on either monotherapy or combination therapy depending on the prostate volume and then reassessed at 3 and 6 months after starting drug therapy. Conclusion: Medical treatment for LUTS/BPH aims to produce rapid, sustained, and safety improvements in the lower urinary tract symptoms associated with benign prostatic hyperplasia that affect the quality of life in the majority of men over the age of 45. Combined therapy of an α1-adrenergic receptor antagonist (tamsulosin) plus a 5-alpha reductase inhibitor (dutasteride) is a good approach for meeting these objectives.

• 1.   Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet 2003;361:1359– 67.
• 2.   Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on the bladder. European Urology 2006;49:651–9.
• 3.   Sountoulides P, van Dijk MM, Wijkstra H, de la Rosette JJMCH, Michel MC. Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction. World J Urol 2010;28:3–8.
• 4.   Lerner LB, McVary, KT, Barry MJ et al.: Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline part I, initial work-up and medical management. J Urol 2021; 206: 806.
• 5.   Singh D, Mete U, Mandal A, Singh S. A Comparative Randomized Prospective Study to Evaluate Efficacy and Safety of Combination of Tamsulosin and Tadalafil vs. Tamsulosin or Tadalafil Alone in Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia. The Journal Of Sexual Medicine 2014;11:187-196.
• 6.   Pande S, Hazra A, Kundu AK. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial. Indian J Pharmacol 2014;46:601-7.
• 7.   Casabe A, Roehrbron CG, Da Pozzo LF, et al.. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol 2014; 191: 727–733.
• 8.   Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004;64:1081–8.
• 9.   Drake MJ, Chapple C, Sokol R, Oelke M, Traudtner K, Klaver M, Drogendijk T, Van Kerrebroeck P; NEPTUNE Study Group. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol. 2015 Feb;67(2):262-70.
• 10.   Dr Dushyant Kumar Garg, Dr Nikhil Mahajan, Dr Karam Singh, Dr Varun Garg, Combination Therapy of Dutasteride and Silodosin – An Effective Modality to Treat LUTS In BPH, Indian Journal of Applied Research: Volume-7/isuue-9/ September-2017
• 11.   Manohar CS, Nagabhushana M, Karthikeyan VS, et al.. Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH – a double-blind randomized trial. Cent European J Urol. 2017; 70: 148-153.
• 12.   Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, et al. The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study. EurUrol 2010;57:123–31
• 13.   Yu H-J, Lin AT-L, Yang SS-D, Tsui K-H, Wu H-C, Cheng C-L, et al. Noninferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). BJU International. 2011 May 18;108(11):1843–8.

Data Sharing Statement

Funding